[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585516":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":34,"centralContacts":38,"locations":45,"responsibleParty":62,"collaborators":43,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":43,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":43,"studyType":77,"phases":78,"briefSummary":81,"conditions":82,"keywords":43,"overallStatus":48,"whyStopped":43,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part1-Group A","EXPERIMENTAL","ZG005 20mg\u002Fkg IV Q3W+Gecacitinib 50mg po Bid",[13,14],"Biological: ZG005 for Injection","Drug: Gecacitinib Hydrochloride Tablets",{"label":16,"type":10,"description":17,"interventionNames":18},"Part1-Group B","ZG005 20mg\u002Fkg Q3W+Gecacitinib 100mg po Bid",[13,14],[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","ZG005 for Injection","intravenous infusion",[9,16],[26],"ZG005",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Gecacitinib Hydrochloride Tablets","Oral",[9,16],[33],"Gecacitinib",[35],{"name":36,"affiliation":5,"role":37},"Jason Wu","STUDY_CHAIR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Cong Zhang","CONTACT","17602176888",null,"zhangc@zelgen.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":43,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Shanghai Chest Hospital","RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":54,"coordinates":55},"Point",[56,57],121.45806,31.22222,{"lat":57,"lon":56},[60],{"name":61,"role":41,"phone":43,"phoneExt":43,"email":43},"Xinghao Ai",{"type":63,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100585516","phase-1-study-of-zg005-combined-with-gecacitinib-in-patients-with-advanced-non-small-cell-lung-cancer-100585516",false,"NCT06903377","Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I\u002FII Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Fully understand this study and voluntarily sign the ICF.\n* Age 18-75 years, no gender restriction.\n* Patients with locally advanced or recurrent\u002Fmetastatic squamous and\u002For non-squamous non-small cell lung cancer confirmed by histology\u002Fcytology, unsuitable for radical therapy.\n\nExclusion Criteria:\n\n* Medical history, CT scan, or MRI indicates the presence of CNS metastases.\n* Other malignancies within 5 years.\n* Any other reason deeming the participant unsuitable for the study, as judged by the investigator.","ALL","18 Years","75 Years",{"count":75,"type":76},50,"ESTIMATED","INTERVENTIONAL",[79,80],"PHASE1","PHASE2","This is a multicenter Phase I\u002FII study for patients with advanced non-small cell lung cancer who have failed PD-1\u002FL1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.",[83],"Non-small Cell Lung Cancer","2025-12-30",{"date":86,"type":87},"2026-01-05","ACTUAL",{"date":89,"type":87},"2025-05-23",{"date":91,"type":76},"2027-05",{"name":5,"class":6},1]